ORP Grant History

The NCCN Oncology Research Program (ORP) is a comprehensive program of research platforms and scientific advisors to foster the development of world-class therapies to treat people with cancer. The NCCN ORP’s core services focus on assisting companies with drug development plans and strategies, facilitating the conduct of preclinical, translational, and clinical research at NCCN Member Institutions, and ensuring that results of funded research projects are publicly disseminated. The NCCN ORP can also establish research collaborations between NCCN Member Institutions and industry in Phase IV, quality-of-life, cancer prevention, and outcomes research.

The NCCN ORP has collaborated with pharmaceutical and biotechnology companies to support investigator-initiated trials to study both FDA-approved and investigational agents/devices, to seek novel enhanced, effective, and efficient cancer therapy. In addition, the ORP is funding projects to develop new insights into cancer care delivery outcomes and quality, as well as identify solutions to barriers affecting optimal cancer management.

NCCN has worked with the following companies and compounds to support investigator-initiated research and quality improvement initiatives:

  • Abraxis BioScience, Inc. – clinical studies of nab-paclitaxel
  • Allos Therapeutics, Inc. – clinical studies of pralatrexate
  • Astellas Scientific and Medical Affairs, Inc. – for preclinical and clinical studies of enzalutamide
  • AstraZeneca Pharmaceuticals, LP – for clinical, preclinical and correlative studies of osimertinib
  • AstraZeneca Pharmaceuticals, LP – quality improvement projects in non-small cell lung cancer
  • AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in ovarian cancer
  • AVEO Pharmaceuticals, Inc. – clinical studies of tivozanib
  • Bayer HealthCare Pharmaceuticals, Inc. – clinical studies of sorafenib
  • Boehringer Ingelheim, Pharmaceuticals, Inc. – clinical studies of afatinib
  • Boehringer Ingelheim Pharmaceuticals, Inc. – clinical studies of nintedanib
  • Boehringer Ingelheim Pharmaceuticals, Inc. – clinical studies of volasertib
  • Boehringer Ingelheim Pharmaceuticals, Inc. – studies of combination therapies with afatinib in lung cancer
  • Bristol-Myers Squibb Company and ImClone Systems Incorporated – clinical studies of cetuximab in head and neck cancers and bladder cancers
  • Cephalon, Inc. – clinical studies of bendamustine
  • Genentech, Inc. – mutli-institutional clinical study of carboplatin, pemetrexed, and bevaciumab, with or without atezolizumab, in lung cancer
  • GlaxoSmithKline LLC – pre-clinical and clinical studies of dabrafenib
  • GlaxoSmithKline LLC – clinical studies of pazopanib
  • GlaxoSmithKline LLC – clinical studies of ofatumumab
  • GlaxoSmithKline LLC – clinical studies of trametinib
  • GlaxoSmithKline LLC – multi-institutional clinical study of trametinib in melanoma with BRAF non-V600 mutations
  • ImmunoGen, Inc. – pre-clinical studies and clinical studies of mirvetuximab soravtansine (IMGN853)
  • Eli Lilly and Company – pre-clinical and clinical studies of abemaciclib
  • Merck & Co., Inc. – clinical studies of vorinostat
  • Onyx Pharmaceuticals, Inc. – clinical studies of carfilzomib
  • Peregrine Pharmaceuticals, Inc. – clinical and correlative studies of bavituximab in combination with other therapeutic strategies for the treatment of solid tumors
  • Pfizer, Inc. – clinical studies of irinotecan and celecoxib
  • Pfizer, Inc. – preclinical and specialized imaging studies of sunitinib
  • Pfizer, Inc. – clinical studies of axitinib
  • Pfizer, Inc. – studies using components of EMBRACE
  • Puma Biotechnology – clinical and correlative studies of neratinib
  • Roche Laboratories, Inc. – clinical studies of capecitabine
  • Taiho Oncology – clinical studies of trifluridine/tipiracil
  • Taiho Oncology – clinical studies of futibatinib
  • Taiho Oncology – clinical studies of decitabine/cedazuridine
  • Wyeth – clinical studies of temsirolimus

Abemaciclib Studies
Afatinib Studies
Afatinib Combination Studies
Axitinib Studies
Bavituximab Studies
Bendamustine Studies
Capecitabine Studies
Carfilzomib Studies
Celecoxib Studies
Cetuximab Studies
Dabrafenib Studies
Decitabine/Cedazuridine Studies
EMBRACE Component Studies
Enzalutamide Studies
Futibatinib Studies
Irinotecan Studies
Mirvetuximab Soravtansine (Preclinical)
Mirvetuximab Soravtansine (Clinical)
nab-Paclitaxel Studies
Nintedanib Studies
Ofatumumab Studies
Osimertinib Studies
Pazopanib Studies
Pralatrexate Studies
Quality Improvement Studies – Lung
Quality Improvement Studies – Ovarian
Sorafenib Studies
Sunitinib Studies (Preclinical)
Sunitinib Studies (Specialized Imaging)
Temsirolimus Studies
Tivozanib Studies
Trametinib Multi-site Clinical Study
Trametinib Studies
Trifluridine/Tipiracil Studies
Vorinostat Studies

Abemaciclib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Aditya Bardia, MDMassachusetts General Hospital Cancer CenterA Prospective, Multi-Center, Biomarker Driven Trial to Evaluate the Efficacy and Safety of Abemaciclib Monotherapy Beyond First Line CDK4/6 Inhibition in ER + Breast Cancer (AMBER)
Mathew Cherian, MBBSThe Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research InstituteRefractory Hormone Receptor Positive Breast Cancer: A Role for Estrogen Receptor β
Inan Olmez, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteA Preclinical Study of Abemaciclib in Combination with Merestinib against Breast Cancer Brain Metastases
Mateusz Opyrchal, MD, PhDWashington University in St. LouisInhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Blockade of ER Positive Breast Cancers
Chenbo Zeng, PhDAbramson Cancer Center at the University of PennsylvaniaPET Imaging of Cell Cycle Arrest for Predicting Response to Abemaciclib Alone or in Combination with Endocrine Therapy

Afatinib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Christine Chung, MD/Jill Gilbert, MDThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins/Vanderbilt-Ingram Cancer CenterPhase I/II Study of Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed by Standard Chemoradiation in HPV Negative or High-Risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC Patients
Danielle Margalit, MD, MPHDana-Farber/Brigham and Women’s Cancer CenterPhase I Study of Afatinib with Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)
David G. Pfister, MDMemorial Sloan Kettering Cancer CenterPhase I Study of Induction Chemotherapy with Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Lecia Sequist, MD, MPHMassachusetts General Hospital Cancer CenterRandomized Phase II Study Comparing Concise (3 months) versus Prolonged (2 years) Afatinib as Adjuvant Therapy for Patients with Resected Stage I-III NSCLC with EGFR Mutation

Afatinib Combination Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Aarti Bhatia, MD, MPHYale Cancer Center/Smilow Cancer HospitalSingle-Arm Phase II trial of Dual Inhibition of EGFR with Afatinib and Cetuximab with Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Michael Gibson, MD, PhD

Vanderbilt-Ingram Cancer Center

Afatinib and Nivolumab as Treatment of Platinum- and Cetuximab-Refractory Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Sally York, MDVanderbilt-Ingram Cancer CenterPhase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC with Acquired Resistance to First or Third Generation EGFR TKIs

Axitinib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Alan L. Ho, MD, PhDMemorial Sloan Kettering Cancer CenterA Phase II Study of Axitinib (AG-013736) in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Mateusz Opyrchal, MD, PhDRoswell Park Comprehensive Cancer CenterPredictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma
Jonathan Strosberg, MD/Emily Bergsland, MDMoffitt Cancer Center/ UCSF Helen Diller Family Comprehensive Cancer CenterA Phase II Study of Axitinib in Advanced Carcinoid Tumors
Francis P. Worden, MDUniversity of Michigan Comprehensive Cancer CenterPhase II Trial Evaluating Axitinib in Patients with Unresectable, Recurrent or Metastatic Head and Neck Cancer
Paul Swiecicki, MDUniversity of Michigan Comprehensive Cancer CenterPhase II Expansion Trial Evaluating Axitinib in Patients with Unresectable Recurrent, or Metastatic Head and Neck Cancer utilizing Choi Response

Bavituximab Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Jessica Frakes, MDMoffitt Cancer CenterA Phase I trial of Sorafenib and Bavituximab plus Stereotactic Body Radiation Therapy (SBRT) for 1st Line Treatment of Unresectable Hepatocellular Carcinoma
Elizabeth Gerstner, MDMassachusetts General Hospital Cancer CenterPhase II Clinical Trial of Bavituximab with Radiation and Temozolomide for Patients with Newly Diagnosed Glioblastoma
Ranee Mehra, MDThe Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 Study of Pembrolizumab and Bavituximab for Progressive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Bendamustine Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Marc C. Chamberlain, MDUniversity of WashingtonA Phase II Study of Bendamustine (Cephalon, Inc.) in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)
John C. Grecula, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstitutePhase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy (SRT) for Patients with 1-4 Brain Metastases from Solid Malignancies
Rachel M. Layman, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstitutePhase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer
Edward Pan, MDMoffitt Cancer CenterPhase I Study of Bendamustine with Concurrent Whole Brain Radiation Therapy in Patients with Brain Metastases from Solid Tumors
Francisco Robert, MD/Rodolfo Bordoni, MDO'Neal Comprehensive Cancer Center at UAB/Georgia Cancer SpecialistsPhase I/IIa Study of the Novel Combination of Bendamustine with Irinotecan Followed by Etoposide/Carboplatin in Chemonaive Patients with Extensive Stage Small Cell Lung Cancer
Apostolia-Maria Tsimberidou, MD, PhDThe University of Texas MD Anderson Cancer CenterA Phase I Study of Bendamustine and Bevacizumab for Patients with Advanced Cancers

Capecitabine Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Tanios Bekaii-Saab, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteA Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients with Advanced Pancreatic Cancer
Renuka Iyer, MDRoswell Park Comprehensive Cancer CenterMulticenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
Nikhil Khushalani, MDRoswell Park Comprehensive Cancer CenterPhase II Study of Capecitabine in Combination with Oxaliplatin and Radiotherapy for Esophageal and Gastroesophageal Junction Cancer
Andrew Ko, MD/Kimberly Jones, MDUCSF Helen Diller Family Comprehensive Cancer Center/Huntsman Cancer Institute at the University of UtahA Phase I Study, with expanded cohort, of Biweekly Fixed-Dose Rate Gemcitabine plus Capecitabine in Patients with Advanced Pancreatic and Biliary Carcinomas
Daniel Laheru, MDThe Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsThymidylate Synthase (TS) Genotype-Directed Phase II Trial of Oral Capecitabine for 2nd Line Treatment of Advanced Pancreatic Cancer
Mary Mulcahy, MDRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityA Phase II Study of Capecitabine and Oxaliplatin with Radiation for Esophageal and Gastroesophageal Junction Adenocarcinoma
Lakshmi Pendyala, PhDRoswell Park Comprehensive Cancer CenterGene Expression Profiling of Esophageal Cancer in Patients Receiving Oxaliplatin, Capecitabine and Radiation, Exploring Correlations to Response
M. Wasif Saif, MD, MBBSYale University School of MedicineA Phase I/II, Open-Label, Dose Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients with Advanced Pancreatic Carcinoma
Hope Uronis, MDDuke Cancer InstituteCorrelative Biomarker Proposal for A Phase II Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinoma
Robert Warren, MDUCSF Helen Diller Family Comprehensive Cancer CenterA Retrospective Analysis of Thymidylate Synthase (TS) and Thymidine Phosphorylase (TP) Levels and Thymidylate Synthase (TS) Genetic Polymorphisms from Archived Hepatocellular Carcinoma (HCC) Surgical Specimens

Carfilzomib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Jeremy Abramson, MD, MMScMassachusetts General Hospital Cancer CenterPhase I Study of Carfilzomib Plus Belinostat in Relapsed/Refractory non-Hodgkin Lymphoma Subtypes
Charalambos Andreadis, MD, MSCEUCSF Helen Diller Family Comprehensive Cancer CenterA Phase Ib Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory non-Hodgkin Lymphoma
Steven Horwitz, MDMemorial Sloan Kettering Cancer CenterA Phase Ib/IIa Study of Combination Therapy with Carfilzomib, Romidepsin, Lenalidomide in Patients with Relapsed or Refractory B- and T-cell Lymphomas
Stephen Smith, MDFred Hutchinson Cancer Research CenterA Response-Adapted Clinical Trial of Weekly Carfilzomib with or without Rituximab for Waldenström's Macroglobulinemia and Marginal Zone Lymphoma

Celecoxib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Manuel Hidalgo, MD, PhDThe Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBiological Evaluation of Celecoxib in Pancreatic Cancer
Milind Javle, MDRoswell Park Comprehensive Cancer CenterCelecoxib in Combination with Irinotecan (CPT-11), 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer: A Phase I Study
Ritsuko Komaki, MD, FACRThe University of Texas MD Anderson Cancer CenterA Phase I Study of Concurrent CPT-11/Cisplatin and Celecoxib with Radiation Therapy for Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC)
Nancy Lewis, MDFox Chase Cancer CenterA Randomized Trial of Celecoxib +/- Rosiglitazone vs. Placebo in Patients with Early Stage Non-Invasive Bladder Carcinoma
Brian Rini, MDUCSF Helen Diller Family Comprehensive Cancer CenterA Phase II Trial of Celecoxib Plus Interferon-Alpha in Advanced Renal Cell Carcinoma
Manisha Shah, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstitutePhase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma
Charles Shapiro, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteA Phase II Trial of Exemestane (Aromasin) in Combination with Celecoxib (Celebrex) as Neoadjuvant Treatment in Postmenopausal Women with Stage II, III, and IV Breast Cancer
Przemyslaw Twardowski, MDCity of Hope National Medical CenterBiologic Markers of Angiogenesis: A Companion Study to Phase I Trial of Oral Etoposide in Combination with Celecoxib in Patients with Advanced Malignancies and Phase I Trial of Oral Cyclophosphamide in Combination with Celecoxib in Patients with Advanced Malignancies

Cetuximab Studies

COORDINATING CENTER/PROJECT CHAIRPARTICIPATING MEMBER INSTITUTION/PRINCIPAL INVESTIGATORSTUDY
University of Michigan Comprehensive Cancer Center/Maha Hussain, MD, FACPCity of Hope National Medical Center/Przemyslaw Twardowski, MDPhase II Randomized Trial of Gemcitabine and Cisplatin with or without Cetuximab in Patients with Urothelial Carcinoma
Huntsman Cancer Institute at the University of Utah/Neeraj Agarwal, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/Evan Yu, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins/Mario Eisenberger, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Gary MacVicar, MD
Roswell Park Comprehensive Cancer Center/Ellis Levine, MD
Stanford Cancer Institute/Sandy Srinivas, MD
The University of Texas MD Anderson Cancer Center/Arlene Siefker-Radtke, MD
Vanderbilt-Ingram Cancer Center/Igor Puzanov, MD
PARTICIPATING NON-MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR
Boston Medical Center/Gretchen Gignac, MD
Lahey Clinic/Christopher Tretter, MD
University of Southern California/David I. Quinn, MBBS, PhD, FRACP
Wayne State University/Karmanos Cancer Institute/Ulka Vaishampayan, MD
Memorial Sloan Kettering Cancer Center/Matthew Fury, MD, PhDCity of Hope National Medical Center/Dean Lim, MDA Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Fox Chase Cancer Center/Ranee Mehra, MD
Huntsman Cancer Institute at the University of Utah/Neeraj Agarwal, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Bruce Brockstein, MD
Moffitt Cancer Center/Tawee Tanvetyanon, MD
University of Tennessee Cancer Institute/Furhan Yunus, MD
Fred & Pamela Buffett Cancer Center/Sandeep Rajan, MD

Dabrafenib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Paul Chapman, MDMemorial Sloan Kettering Cancer CenterAdjuvant Therapy of Stage IIIC BRAF-mutated Melanoma Patients with GSK2118436
Mark Kelley, MD, MMHC, FACSVanderbilt-Ingram Cancer CenterBiomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-surgical Model of Advanced, Operable Melanoma
Martin McMahon, PhDUCSF Helen Diller Family Comprehensive Cancer CenterMechanisms of BRAF (V600E) Inhibitor Sensitivity or Resistance in Genetically Engineered Mouse Models of Malignant Melanoma
Manisha Shah, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteA Phase I Trial of GSK2118436 (BRAFi) and Pazopanib in Patients with BRAF-mutated Advanced Malignant Solid Tumors
Manisha Shah, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteA Randomized Phase 2 Study of Single Agent GSK2118436 (BRAFi) vs Combination Regimen GSK2118436 (BRAFi) and GSK1120212 (MEKi) in Patients with BRAF Mutated Thyroid Carcinoma

Decitabine/Cedazuridine Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Michael Byrne, DOVanderbilt Ingram Cancer InstitutePhase 2 Study of Decitabine and Cedazuridine in Combination with Venetoclax for AML Relapse after Allogenic Hematopoietic Cell Transplantation
Gurkamal Chatta, MDRoswell Park Comprehensive Cancer CenterA Phase IB Clinical Trial: Improving Outcomes with Androgen Pathway Inhibitors by targeting DNA methyltransferase Activity
Martin D. McCarter, MDUniversity of Colorado Anschutz Medical CampusOral Decitabine/Cedazuridine (Invoqi) in Combination with Nivolumab as a Strategy to Enhance the Efficacy of Immune Checkpoint Blockade in Unresectable or Metastatic Mucosal Melanoma

EMBRACE Component Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Nancy Lin, MDDana-Farber Cancer InstituteThe EMBRACE Program: A Comprehensive Approach to Improve the Care of Patients with Metastatic Breast Cancer
Laura Spring, MDMassachusetts General Hospital Cancer CenterExpanding Precision Medicine for Patients with Metastatic Breast Cancer in the Community: Leveraging Academic Strength and Community Partnership
Aki Morikawa, MD, PhDUniversity of Michigan Rogel Cancer CenterPersonalized Multi-Care: A Tailored Approach to multidisciplinary care coordination delivery for metastatic breast cancer patients with central nervous system metastases
Erin Gillespie, MD & Allison Lipitz-Snyderman, PhDMemorial Sloan Kettering Cancer CenterLeveraging an Academic-Community Partnership Model to Improve the Quality of Radiation Treatment for Metastatic Breast Cancer Patients
Karen Lisa Smith, MD, MPHJohns Hopkins UniversityThe Johns Hopkins Metastatic Breast Cancer Partners Program: Collaborating to Improve Metastatic Breast Cancer Care

Enzalutamide Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Helen Chamberlin, PhDThe Ohio State University Comprehensive Cancer Center –James Cancer Hospital and Solove Research InstituteEvaluating the Efficacy of Enzalutamide Therapy in Preventing Tumor Progression in a Preclinical Mouse Model of Type 1 Endometrial Carcinoma
Ajay Gopal, MDFred Hutchinson Cancer Research Center/ University of Washington/Seattle Cancer Care AllianceAndrogen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide
James Harding, MDMemorial Sloan Kettering Cancer CenterA Multi-Center Phase I/IB Study of Enzalutamide with and without Sorafenib in Advanced Hepatocellular Carcinoma Patients
Hao G. Nguyen, MD, PhDUCSF Helen Diller Family Comprehensive Cancer CenterPhase II Trial of Definitive Radiotherapy with Leuprolide and Enzalutamide in High Risk Prostate Cancer
Shannon Westin, MD, MPHThe University of Texas MD Anderson Cancer CenterA Phase II study with a Limited Safety Lead-In of Enzalutamide in Combination with Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrial Cancer

Futibatinib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Jordi Rodon Ahnert, MD, PhDThe University of Texas MD Anderson Cancer CenterPhase Ib trial of Olaparib in Combination with Futibatinib in All Solid Tumors with BRCA1/2 Alterations
Siqing Fu, MD, PhDThe University of Texas MD Anderson Cancer CenterA Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
S. Roychowdhury, MD, PhDThe Ohio State University CCC - James Cancer Hospital and Solove Research InstituteDeveloping Futibatinib for Use on Novel FGFR Genomic Alterations and in Therapy Combination
Nguyen Hoai Tran, MDMayo Clinic Cancer CenterPhase 2 Study of FRFR4 Inhibitor Futibatinib in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma with FGF19 Expression after First-line Therapy

Irinotecan Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Patrick J. Creaven, MD, PhDRoswell Park Comprehensive Cancer CenterPhase I Study of Irinotecan followed by Capecitabine in Patients with Advanced Breast Carcinoma
Stacy Moulder, MDMoffitt Cancer CenterA Single Arm Phase II Study of Gemcitabine and Irinotecan in Patients with Metastatic Breast Cancer
Pedro Ramirez, MDThe University of Texas MD Anderson Cancer CenterPhase I Trial of Concurrent Weekly CPT-11, Cisplatinum, and Radiotherapy for Patients with Newly Diagnosed Stage IIIb-IVa Cancer of the Uterine Cervix
M. Wasif Saif, MD, MBBSO'Neal Comprehensive Cancer Center at UABA Phase I and Pharmacologic Trial of Sequential Administration of Bi-weekly Gemcitabine as a 24-hour IV Infusion followed by Irinotecan as a 24-hour IV Infusion in Adult Cancer Patients
Charles Shapiro, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstitutePhase II Study of Sequentially Administered Mitomycin and Irinotecan in Patients with Refractory Metastatic and Inflammatory Breast Cancers

Mirvetuximab Soravtansine (Preclinical)

INVESTIGATORMEMBER INSTITUTIONSTUDY
Michael Birrer, MD, PhDMassachusetts General HospitalMechanisms of Sensitivity and Resistance to Mirvetuximab Soravtansine: Ovarian Cancer and Mesothelioma
Michael Birrer, MD, PhDO'Neal Comprehensive Cancer Center at UABMechanisms of Sensitivity and Resistance to Mirvetuximab Soravtansine: Ovarian Cancer and Mesothelioma
Analisa DiFeo, PhDCase Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer InstituteIdentifying Susceptibilities and Candidate Pharmacodynamic Biomarkers for Mirvetuximab Soravtansine in High-Grade Ovarian and Endometrial Cancer
John Hays, MD, PhDThe Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research InstituteRegulation of Folate Receptor Alpha Expression and Mirvetuximab Soravtansine Sensitivity in Endometrial Cancer through Selective Modulation of Estrogen Receptor
Kian-Huat Lim, MDSiteman Cancer Center at Barnes-Jewish Hospital and Washing University School of Medicine89Zr-DFO Labeling of M9346A to Further Characterize the Biology and Efficacy of Mirvetuximab Soravtansine in Animal Models for Future Clinical Applications
Yunfei Wen, PhDThe University of Texas MD Anderson Cancer CenterPromoting Autophagic Cell Death in High-Grade Serous Ovarian Cancer by Mirvetuximab Soravtansine

Mirvetuximab Soravtansine (Clinical)

INVESTIGATORMEMBER INSTITUTIONSTUDY
Kimberly Blackwell, MDDuke Cancer Institute

Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-expressing, Triple Negative Breast Cancer (TNBC) with Residual Disease post Standard Neoadjuvant Chemotherapy

Mihaela Cristea, MDCity of Hope National Medical CenterA Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients with FRα-positive Recurrent Ovarian, Primary Peritoneal, Fallopian tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)
Stacey Moulder, MD, MSCIThe University of Texas MD Anderson Cancer CenterWomen’s Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients with Localized Triple-Negative Breast Cancer (TNBC) with Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), including a Lead in Cohort to Establish Activity in Patients with Metastatic TNBC

nab-Paclitaxel Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Mihaela Cristea, MDCity of Hope National Medical CenterPhase I Trial of Intraperitoneal nab-paclitaxel (Abraxane®) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity
Grace Dy, MDRoswell Park Comprehensive Cancer CenterSPARC Expression in NSCLC is Correlated with Response to nab-paclitaxel
Siqing Fu, MDThe University of Texas MD Anderson Cancer CenterPhase I Trial of  Hepatic Arterial Infusion of Abraxane with a Pharmacokinetic Study in Advanced Solid Cancer Patients with Predominant Hepatic Metastases
Matthew G. Fury, MD, PhDMemorial Sloan Kettering Cancer CenterPhase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane®) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients with Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Thomas Olencki, DOThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteA Phase 2 Study of Weekly Infusion nab-paclitaxel (paclitaxel protein-bound particles for injectable suspension) in Patients with Unresectable and Metastatic Uveal Melanoma
Gregory A. Otterson, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstitutePhase II Trial of Abraxane plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding from VEGF Directed Therapies
Jasgit Sachdev, MDUniversity of Tennessee Cancer InstituteNeoadjuvant Weekly nab-paclitaxel (Abraxane®) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide with Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer

Nintedanib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Patrick Boland, MDRoswell Park Comprehensive Cancer CenterA Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
Grace Dy, MDRoswell Park Comprehensive Cancer CenterA Phase II Randomized Study Evaluating Nintedanib versus Placebo as Prophylaxis against Radiation Pneumonitis in Patients with Unresectable NSCLC Undergoing ChemoRadiation Therapy
Ramaswamy Govindan, MDSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine A Pilot Study of Nintedanib in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Renuka Iyer, MDRoswell Park Comprehensive Cancer CenterMulticenter Phase 2 Trial of Nintedanib (BIBF 1120) in Patients with Carcinoid Tumors

Ofatumumab Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Seema Bhat, MDRoswell Park Comprehensive Cancer CenterA Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia
Jennifer Brown, MD, PhDDana-Farber Cancer InstituteOfatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL
Alessandra Ferrajoli, MDThe University of Texas MD Anderson Cancer CenterPhase II Study of Ofatumumab as front-line treatment in elderly, unfit patients with Chronic Lymphocytic Leukemia (CLL)
Francisco Hernandez-Ilizaturri, MDRoswell Park Comprehensive Cancer CenterOfatumumab (O) in Combination with Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating with Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantle Cell Lymphoma
Shuo Ma, MD, PhDRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityCorrelative Studies in Conjunction with A Phase II Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Osimertinib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Daniel Gomez, MDThe University of Texas MD Anderson Cancer Center Randomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy (LCT) for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR)
Pasi Janne, MD, PhDDana-Farber/Brigham and Women's Cancer Center/ Massachusetts General Hospital Cancer CenterA Phase 2 Study of Osimertinib in Combination with Selumetinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer

Pazopanib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Nilofer S. Azad, MD/Vivek Subbiah, MDThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins/The University of Texas MD Anderson Cancer CenterA Phase I Study Determining the Safety and Tolerability of Combination Therapy with Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK 1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched with Patients with Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Laura QM Chow, MDUniversity of Washington/Seattle Cancer Care AllianceA Phase I Clinical Trial of Pazopanib in Combination with Escalating Doses of Radioactive 131I in Patients with Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake
David Hong, MDThe University of Texas MD Anderson Cancer CenterPhase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy
Herbert I. Hurwitz, MDDuke Cancer InstitutePhase I Dose Escalation of Pazopanib Plus TH302 in Advanced Solid Tumors
Sheetal Kircher, MDRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityA Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumor (PNET)
William D. Tap, MDMemorial Sloan Kettering Cancer CenterA Phase IB/II Study of Gemcitabine and Docetaxel in Combination with Pazopanib (gem/doce/pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Margaret von Mehren, MDFox Chase Cancer CenterPhase II Study Evaluating the Role of Pazopanib in Angiosarcoma

Pralatrexate Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Tanios Bekaii-Saab, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstitutePhase II Study of Pralatrexate and Docetaxel in Patients with Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-Based Therapy
Patrick Boland, MDRoswell Park Comprehensive Cancer CenterPralatrexate in Combination with Oxaliplatin in Advanced Esophago-Gastric Cancer: A Phase II Trial with Predictive Molecular Correlates
Marcela G. del Carmen, MD, MPHMassachusetts General Hospital Cancer CenterPhase I/II Study of Carboplatin and Pralatrexate in Patients with Recurrent Platinum Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Jean L. Grem, MDFred & Pamela Buffett Cancer CenterA Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-Hour Infusion of 5-Fluorouracil Given Every Other Week in Adult Patients with Solid Tumors
Alan L. Ho, MD, PhDMemorial Sloan Kettering Cancer CenterA Multi-Institution Phase II Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Michaela Liedtke, MDStanford Cancer InstituteA Phase I Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma

Quality Improvement Studies - Lung

INVESTIGATORMEMBER INSTITUTIONSTUDY
Charu Aggarwal, MDHospital of the University of Pennsylvania (HUP) and University of Pennsylvania Health System (UPHS) Community Based HospitalsSystem-wide integration of plasma-based next generation sequencing into clinical pathways for detection of NCCN recommended biomarkers to improve the management of patients with metastatic non-squamous NSCLC
Debora Bruno, MD, MS and
Navid Sadri, MD, PhD
University Hospitals – Seidman Cancer Center (UH/SCC)Developing a PREcision meDICine Thoracic (PREDICT) Service in a large practice network: focus on implementation, physician and patient impact
Jennifer Temel, MD and
Joseph Greer, PhD
Massachusetts General Hospital Cancer Center & Affiliate HospitalsRandomized Trial of a Supportive Care Mobile Application (App) to Improve Symptoms, Coping, and Quality of Life in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Quality Improvement Studies - Ovarian

INVESTIGATORMEMBER INSTITUTIONSTUDY
Alexi A Wright, MD, MPH, Hanneke Poort, PhD, Joanna J Arch, PhDDana-Farber Cancer Institute, Abramson Cancer Center at the University of Pennsylvania, University of Colorado Boulder, Colorado Cancer CenterREVITALIZE: A Telehealth Intervention for Women with Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue
Haller J. Smith, MDUniversity of Alabama at BirminghamFeasibility and impact of a comprehensive telehealth program on reducing geographic barriers to treatment and improving symptom management in rural patients with advanced ovarian cancer
Barbara Goff, MD, and Donna L Berry, PhD, RN, AOCNFred Hutchinson Cancer Research Center, Seattle Cancer Care AlliancePatient-centered Education and Support for Women with Advanced Ovarian Cancer

Sorafenib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Ghassan K. Abou-Alfa, MDMemorial Sloan Kettering Cancer CenterEvaluation of Pre- and Post-Treatment pERK and Ask-1 as Part of a Phase II Study of Sorafenib plus Doxorubicin Combination Therapy in Patients with Advanced Hepatocellular Carcinoma with Disease Progression on Initial Sorafenib
Matthew Old, MDThe Ohio State University Comprehensive Cancer Center – James Cancer Hospital And Solove Research InstitutePhase I/II Clinical Trial of Sorafenib in Combination with Cisplatin and Docetaxel in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Yasmin Thanavala, PhDRoswell Park Comprehensive Cancer CenterGranzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC

Sunitinib Studies (Preclinical)

INVESTIGATORMEMBER INSTITUTIONSTUDY
Long Dang, MD, PhDUniversity of Michigan Comprehensive Cancer CenterTargeting Tumor Reactive Response to Antiangiogenic Therapy
Frank Fitzpatrick, PhDHuntsman Cancer Institute at the University of UtahMolecular Determinants of Sunitinib Efficacy
Roberto Pili, MDThe Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsVertical Inhibition of the VEGF Pathway with Sunitinib in Combination with HDAC and mTOR Inhibitors in Renal Cell Carcinoma Models
Sabina Signoretti, MD and
James Mier, MD
Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer CenterTherapy of Renal Cell Carcinoma with Sutent: Mechanism of Acquired Resistance
John Sunwoo, MD, FACSSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of MedicinePreclinical Evaluation of Sunitinib in Squamous Cell Carcinoma of the Head and Neck
Michael Wong, MD, PhD, FRCPCRoswell Park Comprehensive Cancer CenterInhibition of Human Angiosarcoma and Reversal of Chemoresistance by Sunitinib
Sam Yoon, MDDana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer CenterSunitinib with and without Radiation Therapy: Analysis in a Novel Mouse Model of Soft Tissue Sarcomas

Sunitinib Studies (Specialized Imaging)

INVESTIGATORMEMBER INSTITUTIONSTUDY
John Hoffman, MDHuntsman Cancer Institute at the University of UtahSunitinib for Metastatic Renal Cell Cancer with Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Robert G. Maki, MD, PhDMemorial Sloan Kettering Cancer Center18FDG-PET As a Means to Determine Clinical Response in Soft Tissue Sarcomas in Patients Receiving a Continuous Daily Dosing Schedule of Sunitinib
Andrew Quon, MDStanford Cancer InstituteEvaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Jennifer Specht, MDFred Hutchinson Cancer Research Center/Seattle Cancer Care AllianceDCE-MRI and FDG-PET with Kinetic Analysis to Monitor Breast Cancer Response to Neoadjuvant Sunitinib and Metronomic Chemotherapy

Temsirolimus Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Andrew Armstrong, MD, ScMDuke Cancer InstituteImpact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men with Castration Resistant Metastatic Prostate Cancer
Susana M. Campos, MD, MPHDana-Farber/Brigham and Women's Cancer CenterA Phase I/IB Study of AZD2171 (Cediranib) and Temsirolimus in Patients with Advanced Gynecological Malignancies
Sarat Chandarlapaty, MD, PhDMemorial Sloan Kettering Cancer CenterA Phase I/II Trial of Temsirolimus plus Neratinib in Patients with Metastatic HER2-Amplified or Triple- negative Breast Cancer
Warren A. Chow, MDCity of Hope National Medical CenterRandomized, Phase II Trial of AZD6244 alone and AZD6244 plus Temsirolimus for Soft Tissue Sarcomas
Ira Dunkel, MDMemorial Sloan Kettering Cancer CenterPhase I Study of Perifosine with Temsirolimus for Recurrent Pediatric Solid Tumors
R. Kate Kelley, MD/Sheetal Kircher, MDUCSF Helen Diller Family Comprehensive Cancer Center/Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityA Phase I/II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
David Loeb, MD, PhDThe Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase I/II Trial of Torisel® and Liposomal Doxorubicin in Patients with Advanced Soft Tissue and Bone Sarcomas
David Pfister, MDMemorial Sloan Kettering Cancer CenterA Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Eric Sherman, MDMemorial Sloan Kettering Cancer CenterPhase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Sandhya Srinivas, MDStanford Cancer InstituteUsing Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients with Castration-Resistant Prostate Cancer
Furhan Yunus, MD, FACPUniversity of Tennessee Cancer InstituteA Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Tivozanib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Susana Campos, MS, MD, MPHDana-Farber/Brigham and Women's Cancer CenterPlatinum Sensitive Ovarian Cancer: The Use of Tivozanib as Maintenance Therapy Post Chemotherapy in Patients with Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Elizabeth Gerstner, MDMassachusetts General Hospital Cancer CenterPhase II Trial of Tivozanib in Patients with Recurrent Glioblastoma
Renuka Iyer, MDRoswell Park Comprehensive Cancer CenterMulticenter Phase 1b/2 Study of Tivozanib in Patients with Advanced Inoperable Hepatocellular Carcinoma
M. Dror Michaelson, MD, PhDMassachusetts General Hospital Cancer CenterPhase 2 Combination Trial of Tivozanib and Enzalutamide in Men with Advanced Prostate Cancer
Daniela Elena Matei, MDRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityThe Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Trametinib Multi-site Clinical Study

COORDINATING CENTER/PROJECT CHAIRPARTICIPATING MEMBER INSTITUTION/PRINCIPAL INVESTIGATORSTUDY
Douglas Johnson, MDVanderbilt-Ingram Cancer CenterA Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, To Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations
The University of Texas MD Anderson Cancer Center/Michael Davies, MD, PhD
Massachusetts General Hospital Cancer Center/Keith Flaherty, MD
PARTICIPATING NON-MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR
Georgetown University/ Suthee Rapisuwon, MD

Trametinib Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Douglas Adkins, MDSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of MedicineA Phase II Window of Opportunity Trial with GSK1120212 in Surgically Resectable Oral Squamous Cell Cancer
Kristen Keon Ciombor, MDThe Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research InstituteRandomized Phase II Trial of Single Agent MEK Inhibitor GSK1120212 vs 5-fluorouracil or capecitabine in refractory advanced biliary cancer
Adil Daud, MD/ Paul Chapman, MDUCSF Helen Diller Family Comprehensive Cancer Center/ Memorial Sloan Kettering Cancer CenterPhase I/II Trial of the MEK Inhibitor GSK1120212 + PI3Kinase Inhibitor GSK 2126458 in BRAF Wild Type Melanoma (with or without NRAS mutation)
Ursula Matulonis, MDDana-Farber/Brigham and Women's Cancer CenterA Single Arm, Single Stage Phase II Open Label Trial of GSK1120212 and GSK2126458 in Persistent or Recurrent Cervical Cancer
Terence Williams, MD, PhDThe Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research InstituteA Phase I Trial of MEK Inhibitor GSK1120212 in Combination with Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-Mutant Rectal Cancers

Trifluridine/Tipiracil Studies

COORDINATING CENTER/PROJECT CHAIRPARTICIPATING MEMBER INSTITUTION/PRINCIPAL INVESTIGATORSTUDY
Christos Fountzilas, MDRoswell Park Comprehensive Cancer CenterA Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO)
Amit Mahipal, MBBS, MPHMayo ClinicPhase II Trial of Trifluridine/Tipiracil in Combination with Irinotecan in Biliary Tract Cancers
Sarbajit Mukherjee, MD, MSRoswell Park Comprehensive Cancer CenterUse of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal junction (GEJ) Adenocarcinoma

Vorinostat Studies

INVESTIGATORMEMBER INSTITUTIONSTUDY
Emily Chan, MD, PhDVanderbilt-Ingram Cancer CenterPhase I Trial of Chemoradiation with Capecitabine and Vorinostat in Pancreatic Cancer
Griffith Harsh, MD/Mary Pinder-Schenck, MDStanford Cancer Institute/Moffit Cancer CenterPhase I Trial of Vorinostat Concurrent with Stereotactic Radiotherapy in Treatment of Brain Metastases from Non-Small Cell Lung Cancer
Ranee Mehra, MDFox Chase Cancer CenterPhase I Study of the HDAC Inhibitor Vorinostat with Chemotherapy and Radiation Therapy for the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Theodoros N. Teknos, MDThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteA Phase I Trial of Vorinostat in the Treatment of Advanced Oropharyngeal Carcinoma of the Head and Neck